Celgene Co. (NASDAQ:CELG) Shares Acquired by Rational Advisors LLC

Share on StockTwits

Rational Advisors LLC increased its stake in Celgene Co. (NASDAQ:CELG) by 739.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,891 shares of the biopharmaceutical company’s stock after purchasing an additional 9,593 shares during the quarter. Rational Advisors LLC’s holdings in Celgene were worth $1,081,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of CELG. Renaissance Technologies LLC lifted its holdings in Celgene by 85.7% in the second quarter. Renaissance Technologies LLC now owns 8,935,785 shares of the biopharmaceutical company’s stock worth $826,024,000 after purchasing an additional 4,122,685 shares during the period. Nuveen Asset Management LLC lifted its holdings in Celgene by 707.3% in the second quarter. Nuveen Asset Management LLC now owns 4,476,814 shares of the biopharmaceutical company’s stock worth $413,836,000 after purchasing an additional 3,922,247 shares during the period. York Capital Management Global Advisors LLC lifted its holdings in Celgene by 854.8% in the second quarter. York Capital Management Global Advisors LLC now owns 2,588,825 shares of the biopharmaceutical company’s stock worth $239,311,000 after purchasing an additional 2,317,676 shares during the period. TIG Advisors LLC lifted its holdings in Celgene by 77.3% in the second quarter. TIG Advisors LLC now owns 3,583,622 shares of the biopharmaceutical company’s stock worth $331,270,000 after purchasing an additional 1,562,004 shares during the period. Finally, Omni Partners LLP lifted its holdings in Celgene by 207.0% in the second quarter. Omni Partners LLP now owns 1,842,219 shares of the biopharmaceutical company’s stock worth $170,295,000 after purchasing an additional 1,242,219 shares during the period. 72.06% of the stock is owned by institutional investors and hedge funds.

NASDAQ CELG traded up $0.41 on Wednesday, reaching $110.41. The company’s stock had a trading volume of 3,031,000 shares, compared to its average volume of 6,718,989. Celgene Co. has a twelve month low of $58.59 and a twelve month high of $110.70. The company has a debt-to-equity ratio of 1.51, a quick ratio of 2.80 and a current ratio of 2.89. The stock has a market cap of $77.96 billion, a PE ratio of 14.51, a PEG ratio of 0.52 and a beta of 1.41. The firm’s 50 day moving average is $103.38 and its two-hundred day moving average is $97.09.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $2.99 EPS for the quarter, beating analysts’ consensus estimates of $2.70 by $0.29. Celgene had a net margin of 34.63% and a return on equity of 78.15%. The company had revenue of $4.52 billion during the quarter, compared to analyst estimates of $4.39 billion. During the same period in the prior year, the firm earned $2.29 earnings per share. The business’s quarterly revenue was up 16.1% on a year-over-year basis. Equities research analysts anticipate that Celgene Co. will post 10.7 EPS for the current fiscal year.

In other Celgene news, insider Terrie Curran sold 11,338 shares of the company’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $98.27, for a total transaction of $1,114,185.26. Following the completion of the sale, the insider now directly owns 13,493 shares of the company’s stock, valued at $1,325,957.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.39% of the stock is currently owned by corporate insiders.

Several equities research analysts recently weighed in on the stock. Leerink Swann set a $115.00 price objective on shares of Celgene and gave the stock a “hold” rating in a report on Friday, November 1st. BidaskClub raised shares of Celgene from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Robert W. Baird downgraded shares of Celgene from an “outperform” rating to a “neutral” rating and set a $101.00 price target for the company. in a report on Friday, November 1st. ValuEngine downgraded shares of Celgene from a “sell” rating to a “strong sell” rating in a report on Thursday, August 1st. Finally, Wells Fargo & Co set a $110.00 price target on shares of Celgene and gave the company a “hold” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, nineteen have issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $97.31.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

See Also: What is a dividend reinvestment plan?

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.